Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12784532 | 1.00 | TSHR (0.41) | TSHRKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL19413487 | 0.77 | ALDH1A1 (0.38) | TSHRKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL15157176 | 0.76 | AADAT (0.33) | ALDH1A1BRD4 | |
| SCHEMBL12541574 | 0.76 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL18009306 | 0.72 | GAA (0.36) | TSHRKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL9657126 | 0.72 | TSHR (0.35) | TSHRKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL24795957 | 0.72 | CYP19A1 (0.36) | TSHRKMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL21389300 | 0.72 | CYP19A1 (0.36) | TSHRKMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL19155309 | 0.72 | MAPT (0.45) | KMT2AALDH1A1GAASMN1; SMN2KDM4E | |
| SCHEMBL18009296 | 0.72 | NFE2L2 (0.41) | TSHRKMT2AALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309168-A1 | MODIFIED PEPTIDES AND PROTEINS | AMIDEBIO, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8765096-B2 | Methods and compositions for treating and diagnosing kidney disease | ENDOCYTE, INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | LEAMON CHRISTOPHER PAUL (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-8105568-B2 | Vitamin receptor binding drug delivery conjugates | ENDOCYTE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7772405-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100104626-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | TSHR 1536/4885KMT2A 1861/4885ALDH1A1 1932/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | TSHR 377/4885KMT2A 2852/4885ALDH1A1 931/4885 |
| US-20100104626-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | VDR, GC, CYP24A1 | TSHR 428/4885KMT2A 4582/4885ALDH1A1 2229/4885 |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | TSHR 377/4885KMT2A 2852/4885ALDH1A1 931/4885 |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | VDR, GC, CYP24A1 | TSHR 428/4885KMT2A 4582/4885ALDH1A1 2229/4885 |
| US-20080262246-A1 | 3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors | REN, AGTR2, AGTR1 | TSHR 1518/4885KMT2A 2170/4885ALDH1A1 1161/4885 |
| US-20140309168-A1 | MODIFIED PEPTIDES AND PROTEINS | IAPP, VIP, ENPEP | TSHR 3148/4885KMT2A 4144/4885ALDH1A1 4652/4885 |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRNA10, ACHE, SNCA | TSHR 1880/4885KMT2A 771/4885ALDH1A1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.